Adults 18 to 65, any sex, with Cannabis Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Self-report Instruments to Measure Cannabis UsePrimary· During Week 6
Self-reported cannabis inhalations per day during Week 6 as reported by Timeline Followback
Group
Value
95% CI
Cannabidiol
26.72
± 26.96
Placebo
5.256
± 4.34
Sponsor's own description
Investigators aim to determine Epidiolex's promise as a pharmacotherapy for cannabis use disorder. Investigators hypothesize that Epidiolex, when added to medical management, will result in greater reductions in marijuana use compared to placebo as measured by the 2 primary outcome measures: 1) quantitative THC levels and 2) self-report by Timeline Follow Back. Secondary outcome measures will include treatment retention, patient satisfaction, cannabis withdrawal, cannabis craving, depressive symptoms, anxiety symptoms, , compliance, and cigarette use.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07527338 — Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use
· Phase 2, PHASE3
· not yet recruiting
NCT07278505 — Study of Cannabidiol and Neuroimaging on Stress
· Phase 1, PHASE2
· recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
· Phase 2
· recruiting
NCT06381180 — Warrior CARE: Cannabis Behavioral Health
· Phase 1, PHASE2
· not yet recruiting
NCT06854783 — Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers
· Phase 1
· completed
Other recruiting trials for Cannabis Use Disorder
Currently open trials in the same condition.
NCT07523633 — Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder
· Phase 2
· recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis
· NA
· recruiting
NCT07218471 — Cannabis Reduction and Functional Outcomes
· NA
· recruiting
NCT07184983 — RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mclean Hospital
Last refreshed: 25 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03102918.